A viral Revlimid price comparison between the United States and India has renewed discussion about cancer drug costs, generic medicines and patient access.

In an Instagram video posted by the account Spicy Gori, an American woman claimed that one Revlimid pill costs about $900 in the United States. She said she found options in India ranging from approximately Rs 35 to Rs 300 per pill, which she estimated at about 30 cents to $3.

In an Instagram video posted by the account Spicy Gori, an American woman compared what she described as the cost of Revlimid in the United States and India.

The woman said the medicine is taken by a person she identified as Mayan, who has a form of blood cancer.

Revlimid price comparison draws attention to cancer drug costs

The figures presented in the video illustrate why medicine affordability remains a major concern for patients. However, the prices were not independently verified in the source material and may not represent the same dosage, manufacturer, formulation or purchasing conditions.

Actual patient costs can vary depending on whether the medicine is a brand-name or generic version, whether the patient has insurance coverage and whether financial assistance is available.

Why US and India medicine prices can differ

The video prompted commenters to highlight India’s generic medicine industry, which has made many essential medicines available at lower prices than in some Western countries.

Some users said they purchase generic medicines during visits to India because prices can be lower than those available in the United States or Europe.

Other commenters noted that eligible patients may receive subsidized or free treatment for certain illnesses, including cancer, through government hospitals in India. Access can still vary by location, healthcare facility, medicine availability and a patient’s financial circumstances.

Direct comparisons between US and Indian medicine prices therefore require caution. A listed US price may not represent what an insured patient pays, while a lower Indian price may apply to a different manufacturer or generic version.

The Revlimid comparison has attracted attention because it reflects a broader concern for cancer patients: treatment affordability can depend heavily on insurance coverage, generic availability, healthcare programs and the country in which care is received.